BioCentury | Nov 24, 2003
Strategy

Platform acquisitions

...Lead generation/optimization Glaxo (now GlaxoSmithKline) (B) 1995 Affymax $533 Combinatorial chemistry Lead generation/optimization Lexicon 2001 Coelacanth...
BioCentury | Apr 14, 2003
Strategy

Big spenders

...to the drug," said Gregory. Those hires will add to the chemists at the former Coelacanth Corp....
BioCentury | Apr 14, 2003
Strategy

M&A adds fuel to the fire

...newly purchased company. Such was the case when knockout mouse company Lexicon Genetics Inc. acquired Coelacanth Corp....
...for $32 million in stock (see BioCentury, July 16, 2001). LEXG (The Woodlands, Texas) wanted Coelacanth's...
...deals make sense. We wanted chemistry and they gave it to us." Gregory said the Coelacanth...
BioCentury | Oct 1, 2001
Company News

Lexicon Genetics Inc., Pfizer deal

...LEXG's chemistry subsidiary, Lexicon Pharmaceuticals (formerly Coelacanth Corp. ), sold chemical libraries to PFE for non-exclusive use...
BioCentury | Sep 26, 2001
Company News

Lexicon, Pfizer chemical library deal

...LEXG said its subsidiary, Lexicon Pharmaceuticals (formerly Coelacanth ), sold chemical libraries to PFE for non-exclusive...
BioCentury | Sep 4, 2001
Strategy

Back to School 2001: Integration

...as mice engineered to express the human forms of protein targets of interest. In addition, Coelacanth...
BioCentury | Jul 16, 2001
Company News

Coelacanth, Lexicon Genetics Inc. deal

...Coelacanth for 2.9 million LEXG shares at $10.963, or $32 million (see BioCentury, June 18). Coelacanth Corp....
BioCentury | Jul 2, 2001
Strategy

One deal, two paths forward

...play Arena Pharmaceuticals Inc. (ARNA, San Diego, Calif.) and its planned acquisition of chemistry company Coelacanth Corp....
BioCentury | Jun 18, 2001
Strategy

Reinventing chemistry

...also is affecting how customers use libraries from suppliers. According to Alan Main, CEO of Coelacanth Corp....
...a chemistry company selling the same compound library to multiple customers is a viable strategy. Coelacanth...
BioCentury | Jun 18, 2001
Strategy

Lexicon finds chemistry with Coelacanth

...out-licensing its targets or warehousing them. With last week's proposed $32 million stock acquisition of Coelacanth Corp....
...in July, LEXG will establish a Lexicon Pharmaceuticals division for small molecule drug discovery, with Coelacanth...
...with a focus on GPCRs, ion channels and other historically druggable targets. Sands said that Coelacanth...
Items per page:
1 - 10 of 16
BioCentury | Nov 24, 2003
Strategy

Platform acquisitions

...Lead generation/optimization Glaxo (now GlaxoSmithKline) (B) 1995 Affymax $533 Combinatorial chemistry Lead generation/optimization Lexicon 2001 Coelacanth...
BioCentury | Apr 14, 2003
Strategy

Big spenders

...to the drug," said Gregory. Those hires will add to the chemists at the former Coelacanth Corp....
BioCentury | Apr 14, 2003
Strategy

M&A adds fuel to the fire

...newly purchased company. Such was the case when knockout mouse company Lexicon Genetics Inc. acquired Coelacanth Corp....
...for $32 million in stock (see BioCentury, July 16, 2001). LEXG (The Woodlands, Texas) wanted Coelacanth's...
...deals make sense. We wanted chemistry and they gave it to us." Gregory said the Coelacanth...
BioCentury | Oct 1, 2001
Company News

Lexicon Genetics Inc., Pfizer deal

...LEXG's chemistry subsidiary, Lexicon Pharmaceuticals (formerly Coelacanth Corp. ), sold chemical libraries to PFE for non-exclusive use...
BioCentury | Sep 26, 2001
Company News

Lexicon, Pfizer chemical library deal

...LEXG said its subsidiary, Lexicon Pharmaceuticals (formerly Coelacanth ), sold chemical libraries to PFE for non-exclusive...
BioCentury | Sep 4, 2001
Strategy

Back to School 2001: Integration

...as mice engineered to express the human forms of protein targets of interest. In addition, Coelacanth...
BioCentury | Jul 16, 2001
Company News

Coelacanth, Lexicon Genetics Inc. deal

...Coelacanth for 2.9 million LEXG shares at $10.963, or $32 million (see BioCentury, June 18). Coelacanth Corp....
BioCentury | Jul 2, 2001
Strategy

One deal, two paths forward

...play Arena Pharmaceuticals Inc. (ARNA, San Diego, Calif.) and its planned acquisition of chemistry company Coelacanth Corp....
BioCentury | Jun 18, 2001
Strategy

Reinventing chemistry

...also is affecting how customers use libraries from suppliers. According to Alan Main, CEO of Coelacanth Corp....
...a chemistry company selling the same compound library to multiple customers is a viable strategy. Coelacanth...
BioCentury | Jun 18, 2001
Strategy

Lexicon finds chemistry with Coelacanth

...out-licensing its targets or warehousing them. With last week's proposed $32 million stock acquisition of Coelacanth Corp....
...in July, LEXG will establish a Lexicon Pharmaceuticals division for small molecule drug discovery, with Coelacanth...
...with a focus on GPCRs, ion channels and other historically druggable targets. Sands said that Coelacanth...
Items per page:
1 - 10 of 16